You are viewing: Latin America AI in Biotechnology Market analysis
Part of: AI in Biotechnology Market (Global)

The Latin America AI in Biotechnology Market was valued at $158 Million in 2030 and projected to reach to $371.5 Million by 2035, representing a compound annual growth rate of CAGR 17.7%. Latin America's AI in biotechnology market is positioned for substantial growth, driven by increasing computational biology investments and modernization of healthcare infrastructure across the region.

Latin America AI in Biotechnology Market (2030-2035) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Latin America AI in Biotechnology Market Trends and Insights

  • This acceleration reflects Latin America's increasing investment in computational biology, drug discovery automation, and precision medicine initiatives.
  • Latin America is leveraging AI technologies to address regional healthcare challenges, enhance research capabilities, and reduce time-to-market for therapeutic innovations. The forecast period demonstrates Latin America's commitment to modernizing its biotechnology infrastructure through AI integration.
  • Latin America's pharmaceutical and biotech sectors are adopting machine learning for genomic analysis, clinical trial optimization, and biomarker identification.
  • Key drivers include government support for life sciences innovation, rising healthcare expenditure, and growing partnerships between Latin American institutions and global biotech leaders.
  • Latin America's strategic positioning in the global biotech supply chain further accelerates market expansion through 2035..

Key Market Statistics

  • CAGR (2030-2035) CAGR 17.7%
  • Market Size, 2030 ~USD 158 Million
  • Forecast, 2035 ~USD 371.5 Million
  • Geography Latin America

Latin America AI in Biotechnology Market Overview

Rapid Market Expansion :

Latin America's AI in biotechnology market is experiencing accelerated growth, expanding from USD 158.0 million in 2030 to USD 371.5 million by 2035, driven by increased computational biology adoption and drug discovery automation across the region.

Strong CAGR Performance :

The region demonstrates a robust 17.7% compound annual growth rate from 2030-2035, slightly below the global average of 18.5%, indicating competitive market maturation and sustained investment in AI-driven biotechnology solutions.

Precision Medicine Initiative :

Latin American countries are increasingly leveraging AI technologies for precision medicine applications, enabling personalized treatment approaches and improving healthcare outcomes across diverse patient populations in the region.

Drug Discovery Automation :

Investment in AI-powered drug discovery automation is accelerating across Latin America, reducing development timelines and costs while enhancing the region's capacity for pharmaceutical innovation and competitive positioning.

Latin America AI in Biotechnology Market Dynamics

  • Government initiatives supporting digital health transformation and rising pharmaceutical R&D spending are catalyzing market expansion.
  • The region's growing biotech ecosystem, coupled with improving access to AI technologies and cloud computing infrastructure, creates favorable conditions for market penetration. Key growth drivers include rising demand for personalized medicine, automation of drug discovery processes, and enhanced diagnostic capabilities through AI integration.
  • Latin American biotech companies and healthcare institutions are increasingly adopting AI solutions to improve operational efficiency and clinical outcomes.
  • Strategic partnerships with global technology providers and regional investment in talent development are expected to sustain the 17.7% CAGR through 2035, positioning Latin America as an emerging hub for AI-driven biotechnology innovation..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Latin America's AI in biotechnology market will grow at 17.7% CAGR from 2030 to 2035, reaching USD 371.5 million.
      • Latin America is increasingly adopting AI for drug discovery, genomic analysis, and precision medicine applications.
      • Government initiatives and public-private partnerships are driving AI biotechnology investment across Latin America.
      • Latin America's growing healthcare expenditure and research infrastructure support sustained market expansion through 2035.

      AI in Biotechnology Market Report Scope

      Report Metric Details
      Base Year 2030
      Fastest Growing Segment DRUG DISCOVERY (Type)
      Forecast Period 2030–2035
      Growth Rate CAGR of 18.5% from 2030 to 2035
      Largest Segment CLOUD-BASED SOLUTIONS (Deployment Mode)
      Market Size Base Year (Billions) ~USD 9.72 (2030)
      Revenue Forecast (Billions) ~USD 22.72 (2035)
      Segments Covered Offering, Function, Type, Deployment Mode, End User

      Latin America AI in Biotechnology Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Offering

      • End-To-End Solutions
      • Niche Solutions
      • Services
      • Technologies
      • Technology

      By Function

      • Corporate
      • Launch & Commercial
      • Manufacturing & Supply Chain
      • Post-Marketing Surveillance & Patient Support
      • Regulatory Compliance
      • Research & Development

      By Type

      • Adverse Event Reporting
      • Biomarker Discovery
      • Clinical Data Assessment
      • Clinical Development
      • Compliance Monitoring
      • Consulting Services
      • Demand Forecasting
      • Drug Discovery
      • Hybrid Cloud
      • Implementation Services & Ongoing It Support
      • Inventory Management
      • Launch Coordination
      • Logistics Optimization
      • Marketing Operations
      • Medication Adherence
      • Molecular Design & Optimization
      • Monitoring & Drug Adherence
      • Multi Cloud
      • Other Corporate Functions
      • Other Manufacturing & Supply Chain Functions
      • Patient Engagement
      • Patient Monitoring
      • Patient Support Programs
      • Post-Sales & Maintenance Services
      • Predictive Maintenance
      • Predictive Pricing
      • Predictive Toxicity & Risk Monitoring
      • Private Cloud
      • Public Cloud
      • Real-World Evidence (Rwe) Analysis
      • Real-World Evidence(Rwe) Analysis
      • Recruitment
      • Risk Management
      • Sales Force Optimization
      • Site Selection
      • Structure-Activity Relationship (Sar) Modeling
      • Supply Chain Planning
      • Training & Education Services
      • Trial Design

      By Deployment Mode

      • Cloud-Based Solutions
      • On-Premises Solutions

      By End User

      • Biotechnology Companies
      • Clinical Research Organizations
      • Contract Research Organizations
      • Healthcare Providers
      • Pharmaceutical Companies
      • Research Institutes & Labs

      Target Audience

      • Biotech & Pharmaceutical Companies : Latin American and global biotech firms need regional market intelligence to identify expansion opportunities, assess competitive positioning, and develop localized AI-driven drug discovery and precision medicine strategies.
      • Healthcare Technology Providers : AI and software solution vendors targeting Latin America require market data to quantify demand for computational biology platforms, diagnostic AI tools, and healthcare automation solutions across the region.
      • Investment & Venture Capital Firms : Investors evaluating Latin American biotech opportunities need comprehensive market analysis to identify high-growth segments, assess market maturity, and evaluate portfolio companies' regional growth potential.
      • Government & Healthcare Policy Makers : Latin American health ministries and regulatory bodies require market insights to inform digital health policies, R&D funding decisions, and strategic initiatives supporting AI adoption in biotechnology.
      • Research & Consulting Organizations : Market research firms and consultants need detailed Latin America-specific data to support client advisory services, competitive benchmarking, and strategic recommendations in the biotech AI sector.

      Key Companies in the Latin America AI in Biotechnology Market

      CompanyHQOwnershipStrongest segments
      NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI Compute & Networking,Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and genotyping consumables,
      RECURSIONUnited StatesPublic CompanyPlatform collaboration and milestones,Internal pipeline R&D funding (capitalized/other income),Other services and data partnerships,
      SCHRöDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations (e.g., Novartis and others),Drug Discovery – Internal Pipeline,
      BENEVOLENTAIUnited KingdomPrivate CompanyAI discovery platform and licenses,Collaborative R&D projects and services,Custom data/ontology and analytics solutions,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, transplant, viral load),PCR and digital PCR instruments and consumables,
      TEMPUSUnited StatesPublic CompanyOncology NGS diagnostics (xT, xR, solid tumor and hematologic panels),Other diagnostics (PCR profiling, pathology, inherited conditions, pharmacogenomics nP),Data licensing and software (Insights, Lens, Hub, Next, Algos, Organoids, Trials),
      SOPHIA GENETICSSwitzerlandPublic CompanySOPHiA DDM platform subscriptions and usage-based analytics,Implementation, support, and workflow services,Biopharma collaborations and data-driven research solutions,
      PREDICTIVE ONCOLOGYUnited StatesPublic CompanyCompute Services and Treasury Management,Drug Discovery Services,
      XTALPI INC.ChinaPublic CompanyAI-driven drug discovery solutions (hit discovery, optimization, biology, PepiX),Computational software platforms (XFEP, XMolGen, PatSight, XtalGazer),Automation hardware and integrated workstations (XmartChem, ChemPlus),

      NVIDIA CORPORATION

      NVIDIA Corporation is a publicly traded technology company founded in 1993 and headquartered in the United States. With 42,000 employees, the company designs and manufactures graphics processing units and system-on-chip units. NVIDIA serves markets including gaming, professional visualization, data centers, and artificial intelligence.

      ILLUMINA, INC.

      Illumina, Inc. is a publicly traded genomics company founded in 1998 and based in the United States. The company employs 8,625 people and specializes in DNA sequencing and array-based technologies. Illumina's platforms are used for applications in research, clinical diagnostics, and precision medicine.

      RECURSION

      Recursion is a publicly traded biotechnology company founded in 2013 and headquartered in the United States. With 600 employees, the company uses machine learning and high-throughput biology to discover and develop therapeutics. Recursion focuses on identifying novel drug candidates through computational and experimental approaches.

      SCHRöDINGER, INC.

      Schrödinger, Inc. is a publicly traded computational chemistry and drug discovery company founded in 1990 and based in the United States. The company employs 850 people and develops software platforms for molecular simulation and drug design. Schrödinger's tools are used by pharmaceutical and biotechnology companies to accelerate drug development.

      BENEVOLENTAI

      BenevolentAI is a privately held artificial intelligence company founded in 2013 and headquartered in the United Kingdom. With 173 employees, the company applies machine learning and AI to drug discovery and development. BenevolentAI focuses on identifying new therapeutic targets and repurposing existing drugs for various diseases.

      QIAGEN

      QIAGEN is a publicly traded life sciences company founded in 1984 and headquartered in the Netherlands. With 5,500 employees, the company develops and manufactures sample preparation and molecular testing technologies. QIAGEN serves customers in molecular diagnostics, applied testing, and academic research.

      TEMPUS

      Tempus is a publicly traded artificial intelligence and precision medicine company founded in 2015 and based in the United States. With 3,800 employees, the company leverages machine learning and data analytics to improve cancer treatment and outcomes. Tempus analyzes clinical and molecular data to provide actionable insights for oncology care.

      SOPHIA GENETICS

      Sophia Genetics is a publicly traded digital health company founded in 2011 and headquartered in Switzerland. With 415 employees, the company develops AI-powered platforms for genomic data interpretation and clinical decision support. Sophia Genetics serves hospitals, diagnostic laboratories, and research institutions globally.

      PREDICTIVE ONCOLOGY

      Predictive Oncology is a publicly traded cancer diagnostics and treatment company founded in 2002 and based in the United States. With 14 employees, the company develops personalized medicine solutions for oncology patients. Predictive Oncology focuses on tumor profiling and treatment prediction technologies.

      XTALPI INC.

      XtalPi Inc. is a publicly traded artificial intelligence and drug discovery company founded in 2015 and headquartered in China. The company uses machine learning and computational chemistry to accelerate drug discovery and development. XtalPi focuses on molecular simulation and structure-based drug design.

      Latin America vs. other regions

      HowLatin America compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 4418.5 Million · 19.3% wtd CAGR ·
      Europe
      ~USD 3202.5 Million · 20.3% wtd CAGR ·
      Asia Pacific
      ~USD 2751.7 Million · 21.1% wtd CAGR ·
      Middle East & Africa
      ~USD 198 Million · 15.7% wtd CAGR ·

      Countries within Latin America - compare and drill down

      Country2025 size (native)
      BrazilUSD 407 Million
      MexicoUSD 142.3 Million

      Country market size visualization

      Brazil
      USD 407 Million
      Mexico
      USD 142.3 Million

      Reasons to Buy this Report

      • Regional Market Sizing & Forecasts : Obtain precise market valuations for Latin America's AI in biotechnology sector with detailed projections through 2035, enabling accurate budget allocation and strategic planning for regional expansion.
      • Country-Level Granularity : Access market data segmented by major Latin American markets including Brazil and Mexico, identifying high-growth opportunities and tailoring go-to-market strategies for specific countries within the region.
      • Competitive Landscape Intelligence : Understand regional competitive dynamics, key players, and market positioning specific to Latin America's AI biotechnology sector, informing competitive strategy and partnership opportunities.
      • Growth Driver Analysis : Identify region-specific growth catalysts including precision medicine adoption, drug discovery automation trends, and healthcare digitalization initiatives driving the 17.7% CAGR in Latin America.
      • Investment & Partnership Opportunities : Discover emerging investment opportunities and strategic partnership potential across Latin America's biotech ecosystem, supported by detailed market insights and growth trajectory analysis.

      Frequently asked questions

      What is the projected market size for AI in biotechnology in Latin America by 2035?

      Latin America's AI in biotechnology market is projected to reach USD 371.5 million by 2035, growing from USD 158.0 million in 2030.

      What is the CAGR for AI in biotechnology in Latin America?

      Latin America's AI in biotechnology market is expected to grow at a compound annual growth rate of 17.7% between 2030 and 2035.

      Which applications of AI are driving growth in Latin America's biotechnology sector?

      Latin America is experiencing growth in AI applications including drug discovery automation, genomic analysis, clinical trial optimization, and precision medicine development.

      What factors are supporting AI adoption in Latin America's biotechnology industry?

      Latin America's market growth is supported by government life sciences initiatives, increased healthcare spending, institutional research partnerships, and integration into global biotech supply chains.

      How does Latin America's AI biotechnology market compare to global trends?

      Latin America's 17.7% CAGR is competitive with the global market's 18.5% CAGR, reflecting strong regional momentum in AI-driven biotechnology innovation.

      RESEARCH METHODOLOGY

      This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.

      Secondary Research

      The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.

      Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.

      Primary Research

      During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.

      After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.

      In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.

      Breakdown of Primary Interviews

      AI in Biotechnology Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

      AI in Biotechnology Market

      Data Triangulation

      After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.

      Market Definition

      The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.

      Stakeholders

      • Healthcare IT service providers
      • Pharmaceutical/Biopharmaceutical companies
      • Biotechnology firms
      • AI technology providers
      • Academic & research institutions
      • Academic medical centers/universities/hospitals
      • Regulatory agencies
      • Clinical research organizations (CROs)
      • Genomic testing labs
      • Government agencies
      • Startups in AI and biotech
      • Pharmaceutical supply chain partners
      • Consulting firms
      • Clinical trial management system providers
      • Bioinformatics companies
      • Advocacy groups
      • Investors & financial institutions

      Report Objectives

      • To define, describe, and forecast the AI in biotechnology market by offering, function, deployment mode, end user, and region
      • To provide detailed information regarding the major drivers, restraints, opportunities, and challenges influencing market growth
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the AI in biotechnology market in five main regions (and their respective countries): North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To provide key industry insights, such as value chain, regulatory, patent, and recession impact analysis
      • To profile the key players in the market and comprehensively analyze their core competencies
      • To track and analyze competitive developments, such as product launches & upgrades, collaborations, partnerships, acquisitions, investments, contracts, agreements, alliances, mergers, funding, and expansions of the leading players in the market
      • To benchmark players within the market using the company evaluation matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

      Get the Full AI in Biotechnology Market Report

      Full forecast, segment splits, and company analysis for all AI in Biotechnology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status